DeepBio Participates in US CancerX Summit to Promote Cancer Conquest Project

DeepBio, an artificial intelligence (AI)-based digital pathology company, recently attended the ‘CancerX Member Summit’ held in Washington, D.C. from the 4th to the 5th (local time).

CancerX is a public-private partnership established to carry out the Cancer Moonshot project promoted by the Joe Biden administration in the United States. This initiative brings together experts and organizations from various fields to innovate cancer research, accelerate the advancement of cancer treatment, improve patient treatment outcomes, and optimize the use of cancer-related data.

The summit was attended by approximately 150 representatives from the U.S. federal government agencies and private and public sectors involved in CancerX. Keynote speeches, interactive sessions, and workshops were held, and senior officials from the Department of Health and Human Services (HHS) and the Office of the Assistant Secretary for Health and Human Services (OASH) spoke about how to align federal priorities with cutting-edge digital health solutions.

Kim Sun-woo, CEO of DeepBio, participated in a high-level conversation to develop strategic initiatives related to digital innovation and create scalable solutions. “Since joining CancerAx as a member last November, we have been accelerating the development of our pipeline with cancer conquest as our core task,” said Kim. “We will actively express our opinions through sessions and workshops such as the United States Core Data for Interoperability (USCDI+) to improve the interoperability and exchange of cancer-related health information.”

DeepBio, founded in 2015, is a medical AI development company with expertise in deep learning and cancer pathology diagnosis. The company is developing in vitro diagnostic medical device software (IVD SaMD) that implements useful technology to lead to better treatment decisions by greatly helping medical professionals improve the accuracy of cancer diagnosis and determine prognosis.

DeepDx Prostate, DeepBio’s representative prostate cancer analysis AI solution, analyzes high-resolution images (whole slide tissue images) obtained through tissue examination to identify actual cancer lesion sites. It also provides various key indicators such as the Gleason score, which plays an important role in identifying the exact tumor location and in medical staff’s diagnosis, prognosis prediction, and treatment plan establishment.